Vitamin  	Vitamin  	 NNP	O
D  	D  	 NNP	O
receptor  	receptor  	 NN	B-NP
activation  	activation  	 NNS	I-NP
and  	and  	 CC	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease  	disease  	 NN	I-NP
Vitamin  	Vitamin  	 NNP	I-NP
D  	D  	 NNP	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
recently  	recently  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
several  	several  	 JJ	O
renal 	renal 	 NN	B-NP
,  	,  	 ,	O
cardiovascular  	cardiovascular  	 JJ	O
and  	and  	 CC	O
inflammatory  	inflammatory  	 JJ	B-NP
diseases 	diseases 	 NNS	I-NP
,  	,  	 ,	O
beyond  	beyond  	 IN	O
mineral  	mineral  	 NN	O
metabolism  	metabolism  	 NN	O
and  	and  	 CC	O
bone  	bone  	 NN	O
health 	health 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
due  	due  	 JJ	O
in  	in  	 IN	O
part  	part  	 NN	O
to  	to  	 TO	O
widespread  	widespread  	 JJ	O
expression  	expression  	 NN	O
of  	of  	 IN	O
vitamin  	vitamin  	 JJ	B-NP
D  	D  	 NNP	I-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
VDR 	VDR 	 NNP	B-NP
)  	)  	 -RRB-	O
on  	on  	 IN	O
tissues  	tissues  	 NNS	O
and  	and  	 CC	O
cells  	cells  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
heart 	heart 	 NN	O
,  	,  	 ,	O
kidney 	kidney 	 NN	O
,  	,  	 ,	O
immune  	immune  	 JJ	O
cells 	cells 	 NNS	O
,  	,  	 ,	O
brain  	brain  	 NN	O
and  	and  	 CC	O
muscle 	muscle 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
chronic  	chronic  	 JJ	B-NP
kidney  	kidney  	 NN	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CKD 	CKD 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
other  	other  	 JJ	O
chronic  	chronic  	 JJ	B-NP
disorders 	disorders 	 NNS	I-NP
,  	,  	 ,	O
vitamin  	vitamin  	 VBG	O
D  	D  	 NNP	O
deficiency  	deficiency  	 NN	O
[ 	[ 	 -LRB-	O
serum  	serum  	 CD	B-NP
25 	25 	 CD	I-NP
( 	( 	 -LRB-	I-NP
OH 	OH 	 NNP	I-NP
) 	) 	 -RRB-	I-NP
D  	D  	 NNP	I-NP
< 	< 	 SYM	O
20  	20  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
mL 	mL 	 NN	I-NP
]  	]  	 -RRB-	O
is  	is  	 VBZ	O
very  	very  	 RB	O
common  	common  	 JJ	O
and  	and  	 CC	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
adverse  	adverse  	 JJ	O
outcomes 	outcomes 	 NNS	O
.  	.  	 .	O
Paricalcitol 	Paricalcitol 	 NNP	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
selective  	selective  	 JJ	B-NP
activator  	activator  	 NN	I-NP
of  	of  	 IN	I-NP
VDR 	VDR 	 NNP	I-NP
,  	,  	 ,	O
has  	has  	 VBZ	O
demonstrated  	demonstrated  	 VBN	O
in  	in  	 IN	O
several  	several  	 JJ	O
experimental  	experimental  	 JJ	O
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
of  	of  	 IN	O
diabetic  	diabetic  	 NN	O
and  	and  	 CC	O
non-diabetic  	non-diabetic  	 NNP	B-NP
CKD  	CKD  	 NNP	I-NP
a  	a  	 DT	O
favourable  	favourable  	 JJ	O
profile  	profile  	 NN	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
other  	other  	 JJ	O
VDR  	VDR  	 NNP	B-NP
activators 	activators 	 NN	I-NP
,  	,  	 ,	O
alone  	alone  	 RB	O
or  	or  	 CC	O
as  	as  	 IN	O
add-on  	add-on  	 JJ	O
to  	to  	 TO	O
standard  	standard  	 JJ	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
beneficial  	beneficial  	 JJ	O
effects  	effects  	 NNS	O
are  	are  	 VBP	O
mediated  	mediated  	 VBN	O
by  	by  	 IN	O
different  	different  	 JJ	O
actions  	actions  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
reduction  	reduction  	 NN	O
of  	of  	 IN	O
oxidative  	oxidative  	 JJ	B-NP
stress 	stress 	 NN	I-NP
,  	,  	 ,	O
inflammation 	inflammation 	 NN	B-NP
,  	,  	 ,	O
downregulation  	downregulation  	 VBG	O
of  	of  	 IN	O
cardiac  	cardiac  	 JJ	B-NP
and  	and  	 CC	O
renal  	renal  	 JJ	B-NP
renin  	renin  	 JJ	I-NP
expression 	expression 	 NN	I-NP
,  	,  	 ,	O
downregulation  	downregulation  	 VBG	O
of  	of  	 IN	O
calcifying  	calcifying  	 JJ	O
genes  	genes  	 NNS	O
and  	and  	 CC	O
direct  	direct  	 JJ	O
vascular  	vascular  	 JJ	B-NP
protective  	protective  	 JJ	I-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
paricalcitol  	paricalcitol  	 JJ	O
beneficial  	beneficial  	 JJ	O
effects  	effects  	 NNS	O
may  	may  	 MD	O
be  	be  	 VB	O
independent  	independent  	 JJ	O
of  	of  	 IN	O
baseline  	baseline  	 FW	B-NP
serum  	serum  	 FW	I-NP
parathyroid  	parathyroid  	 FW	I-NP
hormone  	hormone  	 FW	I-NP
( 	( 	 -LRB-	O
PTH 	PTH 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
calcium  	calcium  	 NN	B-NP
and  	and  	 CC	O
phosphate  	phosphate  	 JJ	B-NP
levels 	levels 	 NNS	I-NP
.  	.  	 .	O
These  	These  	 DT	O
benefits  	benefits  	 NNS	O
should  	should  	 MD	O
be  	be  	 VB	O
confirmed  	confirmed  	 VBN	O
in  	in  	 IN	O
large  	large  	 JJ	O
and  	and  	 CC	O
well-designed  	well-designed  	 JJ	O
ongoing  	ongoing  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trials 	trials 	 NNS	I-NP
.  	.  	 .	O
